BIOSPAIN 2018 consolidates the congress as the 5th world biotechnology event

Paula Cañal
Oct 11, 2018

The Spanish Association of Biocompanies (ASEBIO) and the Regional Government of Andalusia have concluded the 9th edition of the International Meeting on Biotechnology BIOSPAIN 2018, which has broken attendance records and is crowned as the fifth world event on biotechnology.

During the inauguration of the congress, Ion Arocena, director of ASEBIO, wanted to highlight the improvement in attendance compared to the previous edition thanks to "a programme aligned with the industry's priorities". One of the main indicators of this success has been the number of meetings arranged by means of the partnering system used during the congress, with which about 4,500 meetings between attendees were calculated.

The Biotechnology Business Institute's team travelled to Seville to participate in the new edition of BIOSPAIN, an event to which it is assiduous. The directors of the center, Juan Garcia and Natalia Oñate, took the opportunity to publicize the activity of the center, networking and strength alliances with the Spanish and international biotech community.

The aim of this ninth edition has been "to enhance the value of the Spanish biotechnology ecosystem to investors and market players both nationally and internationally," explained the director of ASEBIO during the presentation of the event in Seville. In this sense, the congress brought together more than 600 companies from 30 countries, more than 200 exhibitors and almost 50 investors of great European relevance in Life Sciences. 

The main attendance that has highlighted in this edition has been the presence of the Top Ten of investment funds, that manage more than 8,000 million euros of assets in life sciences. Key players in the development of national biotechnology such as Ysios Capital Partners, Fund+, Johnson & Johnson Innovation, Kreos Capital Partners, Forbion Capital, Kreos Capital, Medicxi and M Ventures are some of the investors who attended the congress. 

To this participation is added the interest of the big names in the sector. For the first time, the major pharmaceutical companies took part in BIOSPAIN, including Johnson & Johnson, Lilly, MSD and Novartis. Big Pharma presented their development strategies in search of new alliances with biotech start-ups. "We have managed to turn it into the main platform for boosting international financing and business collaborations at the service of the Spanish biotech industry", added Arocena.

Once again, the biomedical area, agroalimentary and industrial biotechnology and access to financing were the central axis of the meeting. Other current topics, such as advanced therapies, biobanks, circular economy, artificial intelligence, genetic editing, immunotherapy, precision medicine and antibiotic resistance have been other subjects of interest throughout the congress.


Latest news

The Biotechnology Business Institute closes the 5th edition of the Scientific MBA in Lifesciences with a great success and four projects developing drug candidates.

Four drug candidates targeting three indications, Breast Cancer, Chron’s Syndrome and NASH (nonalcoholic steatohepatitis), were presented by our students in the closing ceremony of the Scientific MBA’s as a result of a year developing different intellectual properties for potential new treatments

BBI Case Study in International Strategy. Aortyx, a success case in early stage funding for medical device focus in aortic disease

During the evening of the BBI Open Day a study case in early stage funding was presented by Jordi Martorell, Patrick O’Brien, Lifesciences consultant, and William Hariri, Director at Alira Health. The main objective of the evening was to understand how to develop and international strategy for medical devices.

The Biotechnology Business Institute closes the first BBI Open Day with great success inspiring young scientific professionals

The importance of scientific profiles in a society based in innovation and how their professional development in management can contribute to drug discovery, were some of the main topics presented during the BBI Open Day 2019

The first 2019 BioInternational Seminar is a success and gain interest between scientific profiles with vision in drug discovery

International experts shared their experience and knowledge in the pharmaceutical industry and the biotechnology sector over an evening with young scientific profiles developing their career in the drug discovery field

Filter by category